Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 27

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Effect of Growth Hormone on Neuropsychological Outcomes and Quality of Life of Patients with Traumatic Brain Injury: A Systematic Review

Szarka, Nikolett, Szellar, Dora, Kiss, Szabolcs, Farkas, Nelli, Szakacs, Zsolt, Czigler, Andras, Ungvari, Zoltan, Hegyi, Peter, Buki, Andras, Toth, Peter·2021·Journal of Neurotrauma
DOI 10.1089/neu.2020.7265
Open this paper in CoChat — free account

Abstract

One of the most devastating chronic consequences of traumatic brain injury (TBI) is cognitive impairment. One of the possible underlying causes is growth hormone deficiency (GHD) caused by TBI-induced hypopituitarism. Currently, TBI patients are not routinely screened for pituitary function, and there are no standard therapies when GHD is diagnosed. Further, the possible positive effects of GH replacement on cognitive function and quality of life after TBI are not well established. We aimed to assess the current knowledge regarding the effect of GH therapy on cognitive function and quality of life after TBI. We performed a literature search in PubMed, Embase, and Central ® databases from inception to October 2019. We extracted data on each term of severity (mild-moderate-severe) of TBI with and without GHD, time since injury, parameters of growth hormone treatment (dosing, length), and cognitive outcomes in terms of verbal and non-verbal memory, and executive, emotional, and motor functions, and performed a meta-analysis on the results of a digit span test assessing working memory. We identified 12 studies (containing two randomized controlled trials) with 264 mild-to-moderate-to-severe TBI patients (Glasgow Coma Score [GCS] varied between 6 and 15) with ( n = 255) or without ( n = 9) GHD who received GH therapy. GH was administered subcutaneously in gradually increasing doses, monitoring serum insulin-like growth factor-I (IGF-I) level. After TBI, regardless of GCS, 6–12 months of GH therapy, started in the chronic phase post-TBI, induced a moderate improvement in processing speed and memory capacities, decreased the severity of depression, and led to a marked improvement in quality of life. Limitations include the relatively low number of patients involved and the divergent neuropsychological tests used. These results indicate the need for further multi-centric controlled studies to substantiate the use of GH replacement therapy as a potential tool to alleviate TBI-related cognitive impairment and improve quality of life.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/neu.2020.7265

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 56

  1. 10.1017/cjn.2016.290 · DOI · Paper page
  2. 10.1136/jnnp.66.2.207 · DOI · Paper page
  3. 10.1111/j.1365-2265.2004.02023.x · DOI · Paper page
  4. 10.1016/j.amjmed.2005.02.042 · DOI · Paper page
  5. 10.1210/jc.2004-0511 · DOI · Paper page
  6. 10.3109/02699052.2011.559611 · DOI
  7. 10.1007/s11357-019-00096-w · DOI
  8. 10.1007/s11357-019-00065-3 · DOI
  9. 10.3389/fnagi.2013.00027 · DOI
  10. 10.1152/jn.00947.2005 · DOI
  11. 10.1007/s00221-006-0438-2 · DOI · Paper page
  12. 10.1007/s11357-019-00139-2 · DOI
  13. 10.1111/acel.12372 · DOI
  14. 10.1016/j.ijsu.2010.02.007 · DOI · Paper page
  15. Yang Z.R., , Sun F., , and Zhan S.Y. (2017). Risk on bias assessment: (2) Revised Cochrane risk of bias tool for individually randomized, parallel group trials (RoB2.0)[in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi, 38, 1285–1291.
  16. 10.1136/ebmed-2017-110668 · DOI · Paper page
  17. 10.3389/fendo.2018.00520 · DOI
  18. 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  19. 10.3109/02699051003601705 · DOI · Paper page
  20. 10.1007/s11102-009-0204-0 · DOI · Paper page
  21. 10.3233/JAD-150791 · DOI
  22. 10.1016/S0887-6177(03)00039-8 · DOI · Paper page
  23. 10.3390/ijms161226244 · DOI
  24. 10.1001/archpsyc.1961.01710120031004 · DOI · Paper page
  25. 10.1016/S0140-6736(00)04953-9 · DOI
  26. Kgosidialwa O., , Hakami O., , Muhammad Zia-Ul-Hussnain H., , and Agha A. (2019). Growth hormone deficiency following traumatic brain injury. Int. J. Mol. Sci. 20.
  27. 10.1016/j.rehab.2015.10.009 · DOI
  28. 10.1136/jnnp.46.4.336 · DOI · Paper page
  29. 10.1017/S1355617707070993 · DOI
  30. 10.1089/brain.2014.0283 · DOI
  31. 10.1037/neu0000285 · DOI
  32. 10.1080/01688639208402865 · DOI · Paper page
  33. 10.1016/j.neurol.2017.07.006 · DOI · Paper page
  34. 10.1136/jnnp.41.5.452 · DOI
  35. 10.1136/jnnp.48.1.21 · DOI · Paper page
  36. 10.1017/S1355617708080272 · DOI · Paper page
  37. 10.1038/s41392-019-0036-y · DOI
  38. 10.1556/650.2019.31507 · DOI
  39. 10.1016/0006-8993(91)91485-J · DOI
  40. 10.1530/EJE-08-0279 · DOI
  41. 10.1016/S0306-4530(03)00151-3 · DOI
  42. 10.1111/acel.12583 · DOI · Paper page
  43. 10.1038/jcbfm.2014.156 · DOI · Paper page
  44. Dong X., , Chang G., , Ji X.F., , Tao D.B., , and Wang Y.X. (2014). The relationship between serum insulin-like growth factor I levels and ischemic stroke risk. PloS One, 9, e94845.
  45. 10.1007/s11357-019-00102-1 · DOI
  46. 10.1007/s11357-019-00101-2 · DOI
  47. 10.1016/j.redox.2019.101192 · DOI · Paper page
  48. 10.1007/s11357-019-00078-y · DOI
  49. 10.1007/s11357-019-00111-0 · DOI
  50. 10.1007/s11357-019-00122-x · DOI
  51. Tarantini S., , Valcarcel-Ares N.M., , Yabluchanskiy A., , Fulop G.A., , Hertelendy P., , Gautam T., , Farkas E., , Perz A., , Rabinovitch P.S., , Sonntag W.E., , Csiszar A., , and Ungvari Z. (2018). Treatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice. Aging Cell [Epub ahead of print].
  52. 10.1093/gerona/glx177 · DOI
  53. 10.1007/s11357-017-0003-x · DOI
  54. 10.1152/ajpheart.00780.2016 · DOI · Paper page
  55. 10.1038/jcbfm.2013.143 · DOI
  56. 10.1530/JME-19-0150 · doi:10.1530/jme-19-0150

Cited by

See all 27

Metadata

Authors
Szarka, N., Szellar, D., Kiss, S., Farkas, N., Szakacs, Z., Czigler, A., Ungvari, Z., Hegyi, P., Buki, A., & Toth, P.
Affiliations
  • Institute for Translational Medicine, Medical School, University of Pecs, Pecs, Hungary.
  • Department of Pediatrics, University of Pecs Medical School, Pecs, Hungary.
  • Department of Neurosurgery and Szentagothai Research Center, University of Pecs Medical School, Pecs, Hungary.
  • International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Department of Public Health, Semmelweis University, Budapest, Hungary.
Venue
Journal of Neurotrauma
Publisher
SAGE Publications
Published
2021-05-13
Volume
38
Issue
11
Pages
1467-1483
ISSN
  • 0897-7151
  • 1557-9042
DOI
10.1089/neu.2020.7265
Cited by
27
References
21
Language
en
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.